Alpha 2.0
Login Register
» Authors » Debra Search

Debra Search

Explore the profile of Debra Search including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 67
Followers 0
Related Specialties
Chemistry
Pharmacology
General Medicine
Top 10 Co-Authors
Rongan Zhang
Hossain Monshizadegan
Michael A Blanar
Ranjan Mukherjee
Lawrence J Kennedy
Bowman Miao
Denise Grimm
Litao Zhang
Thomas Harrity
Kenneth T Locke
Published In
J Pharmacol Exp Ther
J Med Chem
PLoS One
ACS Med Chem Lett
Bioorg Med Chem Lett
Affiliations
Soon will be listed here.
Recent Articles
1.
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARα Selective Agonist
Shi Y, Li J, Kennedy L, Tao S, Hernandez A, Lai Z, et al.
ACS Med Chem Lett . 2016 Jun; 7(6):590-4. PMID: 27326332
BMS-711939 (3) is a potent and selective peroxisome proliferator-activated receptor (PPAR) α agonist, with an EC50 of 4 nM for human PPARα and >1000-fold selectivity vs human PPARγ (EC50 =...
2.
P2Y6 receptor potentiates pro-inflammatory responses in macrophages and exhibits differential roles in atherosclerotic lesion development
Garcia R, Yan M, Search D, Zhang R, Carson N, Ryan C, et al.
PLoS One . 2014 Nov; 9(10):e111385. PMID: 25360548
Background: P2Y(6), a purinergic receptor for UDP, is enriched in atherosclerotic lesions and is implicated in pro-inflammatory responses of key vascular cell types and macrophages. Evidence for its involvement in...
3.
Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation
Ye X, Chen S, Zhang H, Locke K, OMalley K, Zhang L, et al.
Bioorg Med Chem Lett . 2010 Apr; 20(9):2933-7. PMID: 20356736
The synthesis and follow-up SAR studies of our development candidate 1 by incorporating 2-aryl-4-oxazolylmethoxy and 2-aryl-4-thiazolylmethoxy moieties into the oxybenzylglycine framework of the PPARalpha/gamma dual agonist muraglitazar is described. SAR...
4.
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453)
Li J, Kennedy L, Shi Y, Tao S, Ye X, Chen S, et al.
J Med Chem . 2010 Mar; 53(7):2854-64. PMID: 20218621
An 1,3-oxybenzylglycine based compound 2 (BMS-687453) was discovered to be a potent and selective peroxisome proliferator activated receptor (PPAR) alpha agonist, with an EC(50) of 10 nM for human PPARalpha...
5.
Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist
Mukherjee R, Locke K, Miao B, Meyers D, Monshizadegan H, Zhang R, et al.
J Pharmacol Exp Ther . 2008 Sep; 327(3):716-26. PMID: 18799592
The first generation peroxisome proliferator-activated receptor (PPAR) alpha agonist gemfibrozil reduces the risk of major cardiovascular events; therefore, more potent PPARalpha agonists for the treatment of cardiovascular diseases have been...
6.
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase...
Ahmad S, Madsen C, Stein P, Janovitz E, Huang C, Ngu K, et al.
J Med Chem . 2008 Apr; 51(9):2722-33. PMID: 18412317
3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGR) inhibitors, more commonly known as statins, represent the gold standard in treating hypercholesterolemia. Although statins are regarded as generally safe, they are known to cause myopathy...
7.
The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins
Madsen C, Janovitz E, Zhang R, Nguyen-Tran V, Ryan C, Yin X, et al.
J Pharmacol Exp Ther . 2007 Nov; 324(2):576-86. PMID: 17986646
Statins, because of their excellent efficacy and manageable safety profile, represent a key component in the current armamentarium for the treatment of hypercholesterolemia. Nonetheless, myopathy remains a safety concern for...